Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer LJV', Esserman L, Rugo HS. Huppert LA, et al. Among authors: esserman l. Ann Oncol. 2024 Oct 28:S0923-7534(24)04070-5. doi: 10.1016/j.annonc.2024.10.018. Online ahead of print. Ann Oncol. 2024. PMID: 39477071
Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS; Athena Breast Health Network Investigators and Advocate Partners; Esserman LJ. Wang T, et al. Among authors: esserman lj. NPJ Breast Cancer. 2024 Oct 14;10(1):90. doi: 10.1038/s41523-024-00681-z. NPJ Breast Cancer. 2024. PMID: 39397069 Free PMC article.
When is prostate cancer really cancer?
Cooperberg MR, Braun AE, Berlin A, Kibel AS, Eggener SE; CANCER-GG1 Writing Group. Cooperberg MR, et al. J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093/jnci/djae200. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39350309
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. Jacob S, et al. Among authors: esserman l. Breast Cancer Res Treat. 2024 Sep 21. doi: 10.1007/s10549-024-07481-w. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39305392
Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.
Fabian CJ, Mudaranthakam DP, Gajewski B, Young K, Winblad O, Khan SA, Garber JE, Esserman LJ, Yee LD, Nye L, Powers KR, Ranallo L, Kreutzjans AL, Pittman K, Altman C, Metheny T, Zelenchuk A, Komm BS, Kimler BF. Fabian CJ, et al. Among authors: esserman lj. Contemp Clin Trials. 2024 Sep 17;146:107697. doi: 10.1016/j.cct.2024.107697. Online ahead of print. Contemp Clin Trials. 2024. PMID: 39293780 Free article.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Shatsky RA, et al. Among authors: esserman lj. Nat Med. 2024 Sep 14. doi: 10.1038/s41591-024-03267-1. Online ahead of print. Nat Med. 2024. PMID: 39277672
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Khoury K, et al. Among authors: esserman lj. Nat Med. 2024 Sep 14. doi: 10.1038/s41591-024-03266-2. Online ahead of print. Nat Med. 2024. PMID: 39277671
Screening Mammography for 40-Year-Old Women-Whose Decision?
Kerlikowske K, Esserman L, Tice JA. Kerlikowske K, et al. Among authors: esserman l. JAMA Intern Med. 2024 Sep 3. doi: 10.1001/jamainternmed.2024.4277. Online ahead of print. JAMA Intern Med. 2024. PMID: 39226037
Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
Northrop A, Christofferson A, Umashankar S, Melisko M, Castillo P, Brown T, Heditsian D, Brain S, Simmons C, Hieken T, Ruddy KJ, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Asare A, Esserman L, Hershman DL, Basu A. Northrop A, et al. Among authors: esserman l. J Am Med Inform Assoc. 2024 Aug 19:ocae190. doi: 10.1093/jamia/ocae190. Online ahead of print. J Am Med Inform Assoc. 2024. PMID: 39158353
478 results